Vis enkel innførsel

dc.contributor.authorNilsen, Tormod Skogstad
dc.contributor.authorScott, Jessica M
dc.contributor.authorMichalski, Meghan
dc.contributor.authorCapaci, Catherine
dc.contributor.authorThomas, Samantha M
dc.contributor.authorHerndon, James E
dc.contributor.authorSasso, John
dc.contributor.authorEves, Neil D
dc.contributor.authorJones, Lee W.
dc.date.accessioned2019-01-04T12:00:01Z
dc.date.available2019-01-04T12:00:01Z
dc.date.created2018-10-11T13:21:46Z
dc.date.issued2018
dc.identifier.citationMedicine & Science in Sports & Exercise. 2018, 50, 1134-1141.nb_NO
dc.identifier.issn0195-9131
dc.identifier.urihttp://hdl.handle.net/11250/2579192
dc.descriptionI Brage finner du siste tekst-versjon av artikkelen, og den kan inneholde ubetydelige forskjeller fra forlagets pdf-versjon. Forlagets pdf-versjon finner du på ovid.com / In Brage you'll find the final text version of the article, and it may contain insignificant differences from the journal's pdf version. The definitive version is available at ovid.comnb_NO
dc.description.abstractPurpose: The purpose of this study was to explore whether methods adapted from oncology pharmacological trials have utility in reporting adherence (tolerability) of exercise treatment in cancer. Methods: Using a retrospective analysis of a randomized trial, 25 prostate cancer patients received an aerobic training regimen of 72 supervised treadmill walking sessions delivered thrice weekly between 55% and 100% of exercise capacity for 24 consecutive weeks. Treatment adherence (tolerability) was assessed using conventional (lost to follow-up and attendance) and exploratory (e.g., permanent discontinuation, dose modification, and relative dose intensity) outcomes. Results: The mean total cumulative ‘‘planned’’ and ‘‘completed’’ dose was 200.7 T 47.6 and 153.8 T 68.8 METIh, respectively, equating to a mean relative dose intensity of 77% T 24%. Two patients (8%) were lost to follow-up, and mean attendance was 79%. A total of 6 (24%) of 25 patients permanently discontinued aerobic training before week 24. Aerobic training was interrupted (missing Q3 consecutive sessions) or dose reduced in a total of 11 (44%) and 24 (96%) patients, respectively; a total 185 (10%) of 1800 training sessions required dose reduction owing to both health-related (all nonserious) and non–health-related adverse events. Eighteen (72%) patients required at least one session to be terminated early; a total of 59 (3%) sessions required early termination. Conclusions: Novel methods for the conduct and reporting of exercise treatment adherence and tolerability may provide important information beyond conventional metrics in patients with cancer.nb_NO
dc.language.isoengnb_NO
dc.subjectaged
dc.subjectexercise therapy
dc.subjectexercise tolerance
dc.subjecthumans
dc.subjectmale
dc.subjectmiddle aged
dc.subjectpatient compliance / statistics & numerical data*
dc.subjectprostatic neoplasms / therapy*
dc.subjectresearch design
dc.subjectretrospective studies
dc.subjectwalking
dc.titleNovel Methods for Reporting of Exercise Dose and Adherence: An Exploratory Analysisnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionacceptedVersionnb_NO
dc.source.journalMedicine & Science in Sports & Exercisenb_NO
dc.identifier.doi10.1249/MSS.0000000000001545
dc.identifier.cristin1619684
dc.description.localcodeSeksjon for fysisk prestasjonsevne / Department of Physical Performancenb_NO
cristin.unitcode150,31,0,0
cristin.unitnameSeksjon for fysisk prestasjonsevne
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode2


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel